What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.”In the company’s words, NCT06325566 on ClinicalTrials.gov
- Tested for
- Degenerative Disc Disease
- Main trialPhase 3
- “The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.”In the company’s words, NCT06325566 on ClinicalTrials.gov
- Other names
- Allogeneic Mesenchymal Precursor Cells
Other drugs for Degenerative Disc Disease
Coming up1
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jul 2027 | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | |
| Phase 3Completed | 30 Jan 2020 | Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure | |
| Phase 3Completed | 15 May 2020 | Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026